论文部分内容阅读
目的 从细胞分子水平对胆囊癌化疗的耐药性进行研究 ,为临床化疗药物的筛选提供理论依据并获得更有效的临床化疗效果。方法 应用免疫组织化学的方法 ,检测胆囊癌中的主要耐药基因拓扑异构酶Ⅱα(topoisomeraseⅡα ,TopoⅡα)、P糖蛋白 (P glycoprotein ,P gp)的表达情况 ,并结合病理组织学分级、临床分期进行研究。结果 TopoⅡα在胆囊癌中的表达 ( 91 7% )明显高于对照组 ( 10 % ) (P <0 0 5 )。P糖蛋白在胆囊癌中的表达 ( 5 8 3 % )高于对照组 ( 2 5 % ) (P <0 0 5 )。TopoⅡα在低分化癌的阳性率明显高于中高分化癌 ,但与肿瘤的TNM分期无关。P糖蛋白的表达与胆囊癌组织学分级、TNM分期均无关。结论 TopoⅡα在胆囊癌中明显高表达 ,选择TopoⅡα抑制剂进行化疗有助于提高化疗效果。
Objective To study the drug resistance of gallbladder carcinoma from cellular and molecular level and to provide theoretical basis for the screening of clinical chemotherapeutic drugs and to obtain more effective clinical chemotherapeutic effect. Methods The expression of topoisomerase Ⅱα (TopoⅡα) and P glycoprotein (P gp) in gallbladder carcinoma was detected by immunohistochemistry, and combined with histopathological grading, clinical Study in stages. Results The expression of TopoⅡα in gallbladder carcinoma (91.7%) was significantly higher than that in the control group (10%) (P <0.05). The expression of P-glycoprotein in gallbladder carcinoma (58.3%) was higher than that in control group (25%) (P <0.05). The positive rate of TopoⅡα in poorly differentiated carcinoma was significantly higher than that in moderately well differentiated carcinoma, but not related to the TNM stage of the tumor. P glycoprotein expression and gallbladder histological grade, TNM staging had nothing to do. Conclusions TopoⅡα is highly expressed in gallbladder carcinoma. Choosing TopoⅡα inhibitor for chemotherapy may be helpful to improve the chemotherapy effect.